Deals blocked by Chinese regulators can make world headlines - think of the plight of Coca-Cola. This has led companies such as Rio Tinto and BHP Billiton to think it may be best to avoid merger review when structuring their deals. This thinking is flawed
Deals blocked by Chinese regulators can make world headlines - think of the plight of Coca-Cola. This has led companies such as Rio Tinto and BHP Billiton to think it may be best to avoid merger review when structuring their deals. This thinking is flawed
A new junior board will open in Shenzhen later this year and will provide a reasonably quick exit for foreign private equity firms. But good structuring is vital to avoid years of delays
New tax implementation rules for corporate restructuring introduce internationally recognised concepts and clarify access to special tax treatments. Recently restructured companies should check their tax position carefully
China is serious about healthcare reform. New top-level guidelines will significantly reduce hospital revenue from medicine sales and promise more orders for medical equipment makers
China's policy on essential medicines will be overhauled as part of wide-ranging healthcare reforms. This may lead to the demise of many local pharmaceutical companies but opportunities in traditional Chinese medicine
For inbound investors, navigating the maze of available structures can be tricky. The development of the PRC Anti-monopoly Law has led to more scrutiny of acquisitions of Chinese companies, causing potential foreign investors to look at other ways of investing in the country; Danone's experience with Wahaha has in turn revealed potential pitfalls for joint ventures